本帖最后由 老马 于 2013-3-13 13:43 编辑 5 f9 Z7 }/ w# Z
/ x, M4 Y' n4 `* r8 [! c' |5 p
健择（吉西他滨）+顺铂+阿瓦斯汀
6 M. d) ^, f @( m: ? Gemzar +Cisplatin + Avastin8 x- ^: o% g3 {8 D+ w
http://annonc.oxfordjournals.org/content/21/9/1804.full
$ Z9 w% |6 K; e! |% _$ E3 [Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
+ X W$ i. X1 g8 V9 f" JPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
( U* @1 a/ u4 C% W. q! C% KResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
& K( Q, X7 J* f
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 256)
+ h: b; F5 r* k, K( u6 X华为网盘附件：+ \+ A8 O* e4 J! t% h' W
【华为网盘】ava.JPG
% F% v1 `* M; Z' {" C2 H. i! @ Q9 p |
显身卡
